Skip to main content
Have a personal or library account? Click to login
Generic Drugs – Decreasing Costs and Room for Increased Number of Kidney Transplantations Cover

Generic Drugs – Decreasing Costs and Room for Increased Number of Kidney Transplantations

By:   
Open Access
|Dec 2015
Read online

References

  1. 1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341(23): 1725-1730.10.1056/NEJM199912023412303
  2. 2. Barnieh L, Yilmaz S, McLaughlin K, et al. The cost of kidney transplant over time. Prog Transplant. 2014; 24(3): 257-62.10.7182/pit2014710
  3. 3. James A, Mannon RB. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable? Curr Transplant Rep. 2015; 2(2): 113-121.10.1007/s40472-015-0052-y
  4. 4. Allard J, Fortin MC. Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients? Can J Kidney Health Dis. 2014; 1: 23.
  5. 5. Generic Drugs. Center for Drug evaluation and Research, U.S. Food and Drug Administration. [Cited 2015 July 13rd] Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm127615.pdf.
  6. 6. Generic Drugs. World Health Organisation. [Cited 2015 July 13rd] Available from: http://www.who.int/trade/glossary/story034/en/.
  7. 7. Generic Drugs. The Free Dictionary. [Cited 2015 July 13rd] Available from: http://medicaldictionary.thefreedictionary.com/Drugs%2c+generic.
  8. 8. EFPIA. The Pharmaceutical Industry in Figures, key data 2014. [Cited 2015 July 13rd] Available from: http://www.efpia.eu/uploads/Figures_2014_Final.pdf.
  9. 9. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther. 2003; (11): 2875-90.10.1016/S0149-2918(03)80340-5
  10. 10. Gondos A, Döhler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation. 2013; 95(2): 267-74.10.1097/TP.0b013e3182708ea823060279
  11. 11. Roodnat JI, Hilbrands LB, Hené RJ, et al. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation. 2014; 98(1): 47-53.10.1097/01.TP.0000442774.46133.7124521775
  12. 12. Gaynor JJ, Ciancio G, Guerra G, et al. Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational study. Transplantation. 2014; 97(9): 925-33.10.1097/01.TP.0000438199.76531.4a24445926
  13. 13. Couzi L, Moulin B, Morin MP, et al. Factors predictive of medication nonadherence after renal transplantation: a French observational study. Transplantation. 2013; 95(2): 326-32.10.1097/TP.0b013e318271d7c123149477
  14. 14. Tamargo J, Le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. Eur J Clin Pharmacol. 2015; 71(5): 549-567.10.1007/s00228-015-1832-0441268825870032
  15. 15. Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012; 15(3): 376-88.10.18433/J3VC8J
  16. 16. Lionberger R, Jiang W, Huang SM, Geba G: Confidence in generic drug substitution. Clin Pharmacol Ther. 2013; 94: 438-440.10.1038/clpt.2013.10424048239
  17. 17. van Gelder T, Gabardi S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transpl Int. 2013; 26: 771-7.10.1111/tri.1207423441971
  18. 18. Waiser J, Slowinski T, Brinker-Paschke A, et al. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant. 2002; 17(7): 1310-7.10.1093/ndt/17.7.131012105257
  19. 19. Spasovski G, Masin-Spasovska J, Ivanovski N. Do we have the same clinical results with Neoral and Equoral treatment in kidney transplant recipients? A pilot study. Transpl Int. 2008; 21(4): 392-4.10.1111/j.1432-2277.2007.00612.x18069921
  20. 20. Borra LC, Roodnat JI, Kal JA, et al. High withinpatient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010; 25(8): 2757-63.10.1093/ndt/gfq09620190242
  21. 21. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012; 12(2): 388-99.10.1111/j.1600-6143.2011.03840.x22081892
  22. 22. Vítko S, Ferkl M. Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. Kidney Int Suppl. 2010; (115): S12-6.10.1038/ki.2009.50620150905
  23. 23. Alloway RR, Sadaka B, Trofe-Clark J, et al. A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients. Am J Transplant. 2012; 12(10): 2825-2831.10.1111/j.1600-6143.2012.04174.x347202022759200
  24. 24. Melilli E, Crespo E, Sandoval D, et al. De novo use of a generic formulation of tacrolimus versus reference tacrolimus in kidney transplantation: evaluation of the clinical results, histology in protocol biopsies, and immunological monitoring. Transpl Int. 2015; 28(11): 1283-90.10.1111/tri.1262626088437
  25. 25. Molnar AO, Fergusson D, Tsampalieros AK, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ. 2015; 350: h3163.10.1136/bmj.h3163447631726101226
  26. 26. Johnston A. Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm Sci Pract. 2013; 20(5): 302-307.10.1136/ejhpharm-2012-000258378663024089632
  27. 27. Harrison JJ, Schiff JR, Coursol CJ, et al. Generic immunosuppression in solid organ transplantation: a Canadian perspective. Transplantation. 2012; 93: 657-665.10.1097/TP.0b013e3182445e9d22267158
  28. 28. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the Use of generic immunosuppressants. Am J Transplant. 2003; 3: 1211-1215.10.1046/j.1600-6143.2003.00212.x14510694
  29. 29. Gordon EJ, Prohaska TR, Sehgal AR. The financial impact of immunosuppressant expenses on new kidney transplant recipients. Clin Transplant. 2008; 22: 738-748.10.1111/j.1399-0012.2008.00869.x259249418673373
  30. 30. van Gelder T. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. Transpl Int. 2011; 24: 1135-1141.10.1111/j.1432-2277.2011.01378.x22032583
  31. 31. Minogue B. The two fundamental duties of the physician. Acad Med. 2000; 75: 431-442.10.1097/00001888-200005000-0000910824765
  32. 32. Maynard A. Health care rationing: doing it better in public and private health care systems. J Health Polit Policy Law. 2013; 38: 1103-1127.10.1215/03616878-237315723974472
  33. 33. Devaney A, Lee M. The use of generic immunosuppression for transplant patients: a UK perspective. Eur J Hosp Pharm. 2013; 20: 272-274. 10.1136/ejhpharm-2013-000336
DOI: https://doi.org/10.1515/prilozi-2015-0061 | Journal eISSN: 1857-8985 (formerly 0350-1914) | Journal ISSN: 1857-9345
Language: English, Russian
Page range: 133 - 138
Published online: Dec 30, 2015
Published in print: Dec 1, 2015
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year

© 2015 Goce Spasovski, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.